WBI Investments LLC Has $1.66 Million Position in Gilead Sciences, Inc. $GILD

WBI Investments LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 31.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,937 shares of the biopharmaceutical company’s stock after selling 6,943 shares during the period. WBI Investments LLC’s holdings in Gilead Sciences were worth $1,656,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Westover Capital Advisors LLC increased its stake in shares of Gilead Sciences by 119.1% in the 2nd quarter. Westover Capital Advisors LLC now owns 15,086 shares of the biopharmaceutical company’s stock valued at $1,673,000 after acquiring an additional 8,199 shares in the last quarter. Rothschild Investment LLC raised its holdings in shares of Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after purchasing an additional 84 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Gilead Sciences by 3.7% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 1,242,172 shares of the biopharmaceutical company’s stock valued at $137,720,000 after purchasing an additional 44,527 shares during the period. Generali Investments Management Co LLC boosted its position in shares of Gilead Sciences by 4.5% during the 2nd quarter. Generali Investments Management Co LLC now owns 13,538 shares of the biopharmaceutical company’s stock worth $1,499,000 after purchasing an additional 579 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $767,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of research reports. Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Rothschild & Co Redburn upped their target price on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Argus increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $129.13.

Gilead Sciences Trading Down 0.7%

Shares of Gilead Sciences stock opened at $124.09 on Tuesday. The company has a market capitalization of $153.96 billion, a P/E ratio of 24.72, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The stock has a fifty day simple moving average of $117.61 and a 200 day simple moving average of $113.02. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $127.68. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period last year, the business earned $2.02 EPS. The business’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the transaction, the insider owned 110,193 shares of the company’s stock, valued at approximately $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 94,646 shares of company stock worth $11,311,286. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.